Marizyme, Inc. is a multi-technology life science company. The Company is engaged in the research, manufacture and commercialization of medical devices, diagnostics and products to address unmet clinical needs. Its products include DuraGraft, MATLOC 1 and Krillase. DuraGraft is a one-time intraoperative vascular graft treatment for use in vascular and bypass surgeries that maintains endothelial function and structure, thereby reducing the incidence and complications of graft failure and improving clinical outcomes post bypass surgery. MATLOC is a lab-on-chip digital screening and diagnostic device platform, which is being developed for quantitative chronic kidney disease (CKD) assessment. Krillase can be used in the treatment of chronic wounds and burns, and other clinical applications. Its DuraGraft is an endothelial damage inhibitor (EDI), indicated for cardiac bypass, peripheral bypass, and other vascular surgeries.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)